Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies against intracellular antigens and tissue injury. Defective apoptosis of activated immune cells leads to the development of autoantibodies in SLE. FasL initiated apoptosis is central for peripheral tolerance. Fas deficiencies in humans and mice predispose toward systemic autoimmunity. SLE is conferred by many genes. The genetic effects may be concentrated by familial clustering or by stratifying of subphenotypes. We have tested polymorphisms and haplotypes in FAS and FASL for association to SLE or subphenotypes in 126 multiplex American SLE pedigrees and found association of the FAS codon214 AC C/T as well as the FASÀ670G4A 0 -codon214 AC C/T 0 haplotype to thrombocytopenia in SLE. Furthermore we have functionally characterized the FAS/FASL promoter polymorphisms associated with SLE in other populations and demonstrate that the activity depends on the allelic variants as well as on the haplotype. The presence of FASÀ670G, which affects STAT1 binding, leads to the highest activity. FASLÀ844C activity is modified by the cis acting À478A and, hence, the haplotype and not the individual variant, determines the promoter activity. We conclude that the FAS/FASL promoter haplotypes are functional and that polymorphisms in FAS may contribute to thrombocytopenia in SLE.
Introduction
Systemic lupus erythematosus (SLE), which is characterized by multiorgan involvement, autoantibody production and tissue injury, is a complex autoimmune disease where environmental as well as genetic factors are clearly important in disease development. The etiology of SLE has a definite genetic component as inferred from increased familial aggregation among siblings and an increased concordance rate among monozygotic twins compared to dizygotic twins. [1] [2] [3] This is further supported by the identification of genetic associations of candidate gene polymorphisms 4, 5 as well as the establishment of linkage to loci in genome-wide scans in SLE. [6] [7] [8] [9] [10] [11] [12] In man, SLE is not often a single gene disorder; the genetic effect generally appears to be conferred by polymorphisms in multiple genes. However, the responsible genes have been difficult to identify since SLE is an unusually heterogeneous disease with a wide range of clinical manifestations among patients. In addition, a relatively large number of genetic effects appear to influence the process leading to the clinical expression and heterogeneity of SLE.
There is evidence for familial aggregation of the various clinical features of SLE. [13] [14] [15] Familial subphenotypes of SLE may be the result of fewer genes compared with overall disease susceptibility, and stratifying by subphenotypes may reduce heterogeneity and facilitate the identification of gene polymorphisms associated with SLE. One such subphenotype, thrombocytopenia, is an independent marker for severe and deadly SLE, [16] [17] [18] [19] and stratification for thrombocytopenia found evidence for linkage to 1q23, a region involving the FasL gene, as well as suggestive linkage to a region on 10q24 in close proximity to FAS. 20 The Fas and FasL genes are considered possible candidate genes in human SLE, since evidence from animal models of lupus with defective Fas and FasL expression point to a role for FasL-mediated apoptosis in the pathogenesis of SLE. The naturally occurring MRL lpr (lymphoproliferative) mouse strain is considered a model for human SLE as these mice develop nephritis, hypergammaglobulinemia, and antinuclear antibodies in addition to lymphadenopathy. The genetic basis for the lpr mouse strain is an insertion of a transposon into intron 2 of the Fas gene that reduces the normal splicing of the FAS transcript leading to the virtual complete absence of Fas expression. 21 The less severe lpr cg strain expresses a nonfunctional Fas caused by a missense mutation within the death domain encoding part of the Fas gene. 22 The gld mouse has a missense mutation in the extracellular domain of FasL, which abrogates its function. 23 The phenotype of these mutations, when bred onto the autoimmune MRL background, is very similar. However, the autoimmune features of the lpr mutation vary on other strains, generating, for example, a less severe phenotype in C57BL6, 129 or C3H mice. 24, 25 Fas is a membrane bound receptor belonging to the TNF-receptor superfamily of death receptors having three extracellular cystein-rich domains and a functional 80 amino-acid residue intracellular death domain. FasL is a type II transmembrane protein of 40 kDa, which belongs to the TNF family. Membrane bound FasL is proteolytically cleaved by metalloproteinases to produce a soluble form. Binding of Fas to its ligand, FasL, triggers the formation of the death-inducing signaling complex (DISC) by recruiting the adaptor molecule FADD, which in turn activates caspase 8. The death receptor initiated pathway then diverges depending on cell type. In type I cells (eg thymocytes, T cells), caspase 8 activates caspase 3 leading to apoptosis, while in type II cells (eg hepatocytes) the mitochondrial pathway releasing cytochrome c is activated followed by formation of the apoptosome, which together with procaspase 9 activates caspase 3. This latter pathway can be inhibited by Bcl-2. 26, 27 The FasL-Fas mediated pathway plays a major role in maintaining immune homeostasis, particularly in activation induced cell death of activated lymphocytes in the periphery after the elimination of antigen, and in the negative selection of thymocytes in the thymus. B-cell homeostasis also seems to be regulated by FasL-Fas interaction. 28 FASL is one of the major effectors of T-cell mediated cytotoxicity. Fas has also been implicated in costimulation and possibly proliferation of memory T cells. 29 We previously scanned the human Fas and FasL genes and identified several sequence variants. 30, 31 The aim of this study was to test the frequent polymorphisms in FAS and FASL for association to SLE, and, especially, to distinctive SLE phenotypes and to test the functional variation of haplotypes of the FAS and FASL promoters upon gene expression.
Results

Association studies
In a screening panel of 23 SLE patients and 23 matched controls, we initially determined the frequency of six variants in FAS and two in FASL, which we identified earlier in a complete mutational scan of these genes. 30, 31 From these we selected three single-nucleotide polymorphisms (SNPs) in FAS and two in FASL, and genotyped the 681 family members of 126 American multiplex SLE pedigrees for these as well as a FASL microsatellite in the 3 0 UTR. 32 Of the FAS polymorphisms evaluated, two were located to the promoter: À690C4T (dbSNP rs 2234758) in a possible mutational hotspot and À670G4A (dbSNP rs 1800682) in a GAS (gamma activation site) binding site. 21 The third is a silent mutation in codon214 (ACC to ACT) (dbSNP rs 2234978) in exon 7, which does not lead to an aminoacid change.
Two FASL polymorphisms, À844C4T and À478A4T, were in the promoter. The À844C4T (dbSNP rs 763110) has been shown to affect the binding site of the transcription factor enhancer-binding protein beta element (EBPb) and the promoter activity of FASL. 26 The microsatellite is a dinucleotide repeat (GT) in 3 0 UTR of FASL (dbSNP rs10640513) very close to exon 4 and might have an effect upon mRNA stability. The distribution and frequencies of the alleles of these FAS and FASL polymorphisms from the founders in the 126 pedigrees evaluated are shown in Table 1 Table 2 ). The definition criteria of thrombocytopenia is o100 000 platelets per microliter. We then constructed a mild SLE subphenotype using only affected individuals with antibodies to nRNP and tested the codon214AC C/T polymorphism for association to this phenotype. We found no association of codon214AC C/T with the mild phenotype ( Table 2 ).
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To determine whether an FAS haplotype spanning a large part of the gene would show the same association in the SLE pedigrees with thrombocytopenia, we established haplotypes from the two frequent polymorphisms, codon214AC C/T in exon 7, and À670G4A affecting a GAS binding site in the promoter, and analyzed haplotypes for association. We found significant evidence for association for the À670 0 -codon214 0 haplotype in these pedigrees (genehunter TDT Po0.005) ( Table 3) . Haplotypes 1 and 3 were preferentially transmitted to affected subjects ( Table 4 ). The À670 0 -codon214 0 haplotype was, however, not associated with the general SLE phenotype (data not shown).
DNA Luciferase assay FAS promoter haplotypes. There are four naturally occurring haplotypes in the À1372 to þ 1 Fas promoter region comprising three polymorphisms: À1194 A4T, À690T4C and À670G4A. The FAS promoter À1194AÀ690TÀ670G haplotype, which lacks the consensus binding site for GAS (STAT1) in position À670, showed the highest constitutive as well as interferon gamma (IFNg) and phorbol myristic acid (PMA) stimulated activity when compared to the three other haplotypes that all have the consensus binding site for STAT1 (Figure 1 ). The expression level of the haplotypes with the preserved STAT1 consensus binding site was more than 40% reduced under all three conditions. There was no significant difference in the promoter activity of the À1194AÀ690TÀ670A and À1194AÀ690CÀ670A haplotypes, while the À1194TÀ690TÀ670A haplotype, which has a mutation of the c-Myb binding site, showed further reduction of the constitutive, IFNg, and PMA stimulated activities. The FAS À1194A4T SNP, which abolishes a c-Myb binding site and thus is interesting from a functional point of view, is too rare (T allele frequency 0.006) to be tested for association to SLE or SLE subphenotypes. In Figure 1 we have combined the results from the À1194AÀ690TÀ670A, À1194TÀ690TÀ 670A and À1194AÀ690CÀ670A haplotypes (here denoted À670A) and compared them to theÀ1194AÀ690TÀ670G haplotype (denoted À670G). The difference in the promoter activity between the À670G haplotype and the À670A haplotype is highly significant when the individual haplotypes or the combined haplotypes are compared. The activity of the insert harboring the À670G allele compared to the combined activities from the three inserts harboring the À670A allele are impressively different, P ¼ 0.000022, 0.000039, and 0.003 under unstimulated, PMA and IFNg stimulated conditions, respectively.
FASL promoter haplotypes. The FASL promoter activity depends on the haplotype and not the individual polymorphisms ( Figure 2 ). The activity of the À844C allele, which has a consensus binding site for EBPb, depends on the cis allele of the À478 polymorphism. The À844CÀ478A haplotype shows the highest activity compared to all other haplotypes. The constitutively and PMA stimulated activities of the À844CÀ478A and À844TÀ478A haplotypes are different, P ¼ 0.003 and 0.03. The activities of the of the À844CÀ478T and À844TÀ478T haplotypes of the constitutively and PMA stimulated activities are also different, P ¼ 0.0004 and 0.002, respectively (Figures 3 and 4) . There is no significant difference in the basal or PMA stimulated promoter activity of the À844TÀ478T and À844TÀ478A haplotypes.
Discussion
We demonstrate for the first time that the presence of the FAS À670A allele in a consensus binding site for the transcription factor GAS lowers the activity of the human FAS promoter. This À670G4A polymorphism in the FAS Functional FAS haplotypes and thrombocytopenia in SLE RL Nolsøe et al promoter is part of an extensive (21884 base pairs) haplotype, spanning a substantial part of the human Fas gene and associated with the phenotype of SLE characterized by thrombocytopenia. We find a highly significant association of a silent codon214 AC C/T polymorphism in exon 7 included in this haplotype with the SLE subphenotype, thrombocytopenia. We also show that the activity of the human FASL promoter depends on a À844C4TÀ478A4T haplotype and not on the individual alleles of either polymorphism. The higher promoter activity of the À844C allele compared to the À844T allele is only present if the À478A allele is in cis. If À478A is in trans this relationship is reversed.
There was no overall association to SLE for any of the FAS or FASL polymorphisms or haplotypes. However, in animal models of SLE, mutations in FAS and FASL are not considered to be sufficient to cause SLE, but rather to contribute to autoimmunity depending on the general genetic background. In the phenotype of SLE characterized by thrombocytopenia, suggestive linkage in areas including the FAS and FASL genes has been established, 20 and we therefore tested the a priori hypothesis that FAS and FASL might contribute to SLE subphenotypes rather than the SLE phenotype itself.
The FAS À670G4A polymorphism has been tested in SLE in three case-control studies in three different ethnic groups, namely Japanese, Korean and Australian SLE patients and healthy controls. The À670A allele was found to be associated with SLE in a case-control study comprising 109 Japanese patients and 140 controls. 34 The authors demonstrated in an electromobility shift assay that only the À670A allele was able to bind the transcription factor STAT1, but they were unable to show a significant difference in promoter activity of the À670A and À670G alleles in a Luciferase reporter study. A possible explanation for this could be the use of the pGL3 basic vector instead of the pGL3 enhancer vector, used by us, and the transfection of an ovarian carcinoma cell line, HeLa, instead of the more relevant Jurkat T cell line. Also, their promoter insert was several hundred base pairs shorter and did not include the silencer region of the promoter between À1035 and À1008. 35 The À670A allele as well as the À670AA genotype were found to be associated with the presence of anti-RNP antibodies in a case-control study comprising 87 Korean SLE patients and 87 controls and confirmed in second Korean SLE cohort of 85 patients. 36 Interestingly, we found marginal significance of association (Po0.03) between the À670 A4G polymorphism and the presence of anti-RNP antibodies using the TDT. In a case-control study in 79 Australian SLE patients and 86 controls, the À670 AA genotype was found to be associated with photosensitivity or oral ulcers. 37 When comparing these three studies with our results, it seems likely that the À670 A4G polymorphism is a genetic contributor to different SLE traits. In our study the À670A allele led to a significantly lower constitutive promoter activity, a difference that was sustained after PMA or IFNg stimulation.
The FASL À844C4T promoter polymorphism has been tested in a case-control study of 211 African-American SLE patients and 150 controls, 38 and the À844CC genotype was found to be associated with SLE. In the same study it was demonstrated that the À844C allele specifically binds the transcription factor EBPb and that the À844C allele has a higher promoter activity compared to the À844T allele in a Luciferase reporter assay. We could not confirm the association to SLE using the TDT in our family collection, not even in the 40 AfricanAmerican families. We further explored the functional consequences of this polymorphism as well as the À478A4T, and could demonstrate that the allele at À478 is crucial for which of the alleles at À844 is most active, and conclude that the haplotype and not the individual alleles determine promoter activity. Even so, the haplotype is not associated in our hands.
We think that FAS and FASL should be considered candidate contributory genes in human SLE. Polymorphisms in these genes do not seem to be sufficient to cause SLE as a phenotype, but may, depending on the genetic background of the individual, act as permissive genes important for the development of the phenotype of SLE characterized by thrombocytopenia. Fas and FasL may exert their effects through modulation of peripheral tolerance.
We found an association of the FAS À670 0 -codon214 0 haplotype as well as the codon214AC C/T polymorphism to the SLE phenotype characterized by thrombocytopenia, but no association of the functional À670A4G polymorphism to this phenotype. There are two possible explanations: (1) There might be an unknown functional polymorphism within the À670 0 -codon214 0 haplotype, which is in tight linkage disequilibrium with the codon214AC C/T , but not the À670G4A polymorphism and as intron 1 is very large, there might be hitherto unknown functional polymorphisms in this intron, which could explain the genetic association we observed. The HapMap shows strong linkage disequilibrium in FAS. (2) The silent codon214AC C/T polymorphism in exon 7 by itself might lead to the observed phenotypic variability by influencing exonic splicing accuracy or efficiency. The phenomenon of exonic splicing skipping is known from other diseases, such as the neuromuscular disease, Spinal muscular atrophy, as reviewed in Cartegni et al. 39 However, the methods for predicting exonic splicing enhancers are still under development. Our results also need to be confirmed in another cohort, as our sample size is relatively small. Clearly, further genetic as well as in vivo studies are required to establish the possible explanations for the genetic association we describe here of the FAS polymorphism and haplotype associated with the SLE phenotype characterized by thrombocytopenia. We conclude that promoter variants in the FAS and FASL genes are functional. The functional promoter variant in FAS is included in a haplotype spanning a substantial part of FAS, which is associated with a severe form of SLE.
Methods
Subjects SLE patients and their families were enrolled in the lupus genetics study as previously described. 6 Medical records were obtained on each potential affected who also completed an extensive questionnaire and interview with a trained physician's assistant or registered nurse to determine clinical manifestations and establish diagnosis. A less comprehensive questionnaire was completed by unaffected family members, but they were also screened for the presence of SLE. The resulting sample contained 126 multiplex SLE pedigrees (77 European-American, 40 African-American and 9 other), including 681 individuals, 294 of which were classified as affected.
DNA isolation
Upon obtaining informed consent, blood samples and/or buccal swabs were collected from each of the participants. Genomic DNA was isolated from peripheral blood mononuclear cells, buccal cell swabs or EBVtransformed cell lines using standard methods.
Genotyping
In a screening panel of SLE patients and matched controls we initially tested the frequency of six FAS and two FASL SNPs, earlier identified by us. 30, 31 PCR-restriction fragment length polymorphism (PCR-RFLP) genotyping of the À690T4C and the À670G4A polymorphisms in the FAS promoter and the codon214AC C/T polymorphism in exon 7 of FAS The presence of a T at À690 and of a G at À670 of the FAS promoter creates an Nde1 and an Mva1 restriction enzyme site, respectively, and the presence of a T at nucleotide 154 in exon 7 creates a Dra1 restriction enzyme site.
FAS promoter primers, which yield a PCR product of 234 bp, were: forward 5 0 AGCTTTGTTTTCCTCTTGAGA and reverse 5 0 CAGAGCGCAGAGGTCC. FAS exon 7 primers were: forward 5 0 TCTCACATGCATTCTACAA GG and reverse 5 0 GCAAGACTCCATCTCAAACAA and give a PCR product of 261 bp.
PCR conditions. Genomic DNA (3 ng) was amplified in a 20 ml reaction volume containing in final concentrations: 0.8 mM forward and reverse primers, 50 mM dNTPs, 1 Â reaction buffer with 1.0-1.5 mM MgCl 2 and 0.5 U of Taq DNA Polymerase (Promega Corporation, Madison, WI, USA). The reactions were carried out in 96-well microtiter plates on a thermal cycler. PCR cycling conditions were 951C (5 min) for one cycle followed by 951C (30 s), 52-561C for different primers (30 s), and 721C (30 s) for 35 cycles. A final cycle of 721C for 10 min completed the reaction.
Digest conditions. The amplified PCR products from the FAS promoter and from exon 7(10 ml) were digested with restriction enzymes in a 20 ml final reaction volume using 2 ml of the accompanying reaction buffer. The PCR amplicon from the FAS promoter was digested with 5 U of Nde1 (Promega Corporation, Madison, WI, USA) for 4 h in Buffer D and with 4 U of Mva1 (Boehringer Mannheim Biochemica, Mannheim, Germany) for 16 h in Buffer H. The PCR amplicon from FAS exon 7 was digested with 5 U of Dra1 (Promega Corporation, Madison, WI, USA) for 16 h in Buffer B. All digestions were carried out at 371C. Controls of known sequenced genotypes were included for every set of digestions carried out. The digested products were resolved on a 2% agarose gel stained with ethidium bromide and visualized using UV transillumination.
Typing for the À844C4T FASL promoter polymorphism We typed for the À844C4T polymorphism by mutagenically separated PCR (MS-PCR). 40 Primer sequences were: forward primer (T allele): 5 0 AATGAAAATGAAAACATTGT, forward primer (C allele): 5 0 TAAATAAGTAAATAAATAAACTGGGCAAA CCTTGAAAATGAAAACAACGC and reverse primer: 5 0 CCCACTTTAGAAATTAGATC and yield PCR products of 114 and 84 bp for the C and T allele, respectively. The PCR conditions with 3 ng of genomic DNA per sample are described in detail in Nolsoe et al.
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Typing for the À478A4T FASL promoter polymorphism We genotyped for the À478A4T promoter variant by analysis of PCR-generated single base primer extension products using the ABI Prism s SNaPshott Multiplex kit from Applied Biosystems. The sequences of the amplification primers and extension primer, respectively, are 5 0 GGGAAGAGATGATGGCAACA (forward primer), 5 0 GAGAATGGTCAGTGGGGCTAT (reverse primer) and 5 0 TATGAATTATAATTGCATGCT (extension primer).
FASL microsatellite
Using biotinylated primers we typed the FASL (GT) n repeat by PCR of 3 ng genomic DNA followed by PAGE, blotting and visualization utilizing a streptavidin-peroxidase (Sigma, St Louis, MO, USA) catalyzed ECL reaction (Amersham Life Science, Cleveland, OH, USA) as described in detail in Nolsoe et al. 31 Forward primer 5 0 BiotACTTCTAAATGCATATCCTGAGCC and reverse primer 5 0 ATCTTGACCAAATGCAACCC yield PCR amplicons varying between 211 and 225 basepairs corresponding to 13-20 GT repeats. Samples homozygous for the different alleles were confirmed by sequencing on an ABI Prism 310 DNA sequencer system (Perkin Elmer, Foster City, CA, USA).
Analysis
Prior to any analysis, sibling, half-sibling, and parentoffspring relationships were confirmed using statistics generated by RELTEST, a feature of SAGE (Statistical Solutions Ltd, Cork, Ireland).
In addition, we stratified pedigrees on the presence of certain clinical manifestations (thrombocytopenia, nRNP, nephritis, oral ulcers, photosensitivity, antibodies to double-stranded DNA, antibodies to Sm, antibodies to Ro and antibodies to La) and analyzed them separately.
Association analysis. The TDT 41 and PDT 42 were used to assess possible association of the FAS and FASL polymorphisms with SLE. Haplotypes were generated and analyzed from GENEHUNTER-PLUS. 43 Linkage disequilibrium values were calculated as follows: Pairwise linkage disequilibrium. Hardy-Weinberg equilibrium was assessed by the simple chi-square test at each locus. Linkage disequilibrium estimates for marker pairs were obtained by first estimating twolocus haplotype frequencies from genotypic data using a likelihood-based approach. Estimated haplotype frequencies from the product of relevant allele frequencies (ie the expected haplotype frequencies under linkage equilibrium) were then subtracted to arrive at the standard measure of linkage disequilibrium. 44 Linkage disequilibrium was then standardized to vary between À1.0 and 1.0 using traditional allele frequency corrections to arrive at the standardized measure of linkage disequilibrium. 45 Since the focus was on the strength of linkage disequilibrium, the sign was ignored. Statistical significance was measured by the w 2 test. All pairwise LD were statistically significant at the a ¼ 0.05 level.
Measurement of the functional activity of FAS and FASL promoter haplotypes by Luciferase activity Reporter gene constructs. FAS: The four different naturally occurring haplotypes of the FAS promoter region À1372 to þ 1 containing the À1194 A4T, À690T4C and À670G4A polymorphic sites were cloned into the pGL3 Enhancer Luciferase Vector (Promega). Upper primer 5 0 CAGGTACCGGGTCTTCCTCATGGCACTA and lower primer 5 0 TACAAGCTTGAGCAATCCTCCGAAGTGA AA introducing a KpnI site at the 5 0 and a HindIII site at the 3 0 of the fragments were used to PCR genomic DNA from individuals with different haplotypes of the FAS promoter. The resultant KpnI-HindIII fragments were cloned into the KpnI-HindIII sites of the pGL3 Enhancer Luciferase Vector using the Original TA cloning s kit (Invitrogen, Carlsbad, CA, USA). Promoter positive clones were identified by PCR using the vector specific forward (5200) and reverse (5201) primers as well as forward primer 5 0 AGCTTTGTTTTCCTCTTGAGA and reverse primer 5 0 CAGAGCGCAGAGGTCC, which amplifies the FAS promoter around the À690T4C and À670G4A polymorphisms. The clones were sequenced to verify the presence of the various polymorphic sites. The four naturally occurring haplotypes of the FAS promoter were: À1194A À690T À670G, À1194A À690T À670A, À1194A À690C À670A and À1194T À690T À670A.
The À1194A À690T À670G haplotype lacks the (GAS) STAT1 binding site in À670, and the À1194T À690T À670A haplotype lacks the c-Myb binding site in À1194.
FASL: The four different naturally occurring haplotypes of the FASL promoter region À870 to þ 100 comprising the À844C4T À478A4T polymorphic sites were cloned into the pGL3 Enhancer Luciferase Vector (Promega) as described above for the FAS promoter constructs. The À200 to þ 100 region of the promoter region is essential for TCR-mediated FasL activation. 46 Upper primer 5 0 TAGGTACCTAAATAAACTGGGCAA ACAATG and lower primer 5 0 CTGAAGCTTGGCA GCTGGTGAGTCAGG introducing a KpnI site at the 5 0 and a HindIII site at the 3 0 of the fragments were used to PCR genomic DNA from individuals with different haplotypes of the FASL promoter. The resultant KpnIHindIII fragments were cloned into the KpnI-HindIII sites of the pGL3 Enhancer Luciferase Vector using the Original TA cloning s kit (Invitrogen, Carlsbad, CA, USA). Promoter positive clones were identified by PCR using the vector specific forward (5200) and reverse (5201) primers as well as forward primer 5 0 AAATAA ACTGGGCAAACAATG and reverse primer 5 0 GGCCA GAGAAGTCACTCC, which amplifies the FASL promoter around the À844C4T À478A4T polymorphisms. The clones were sequenced to verify the presence of the various polymorphic sites. The four naturally occurring haplotypes of the FASL promoter were: À844C À478A, À844T À478A, À844C À478T and À844T À478T.
Luciferase-reporter assay. The human Jurkat Thelper cell line was cultured in RPMI supplemented with 10% FCS (Gibco), penicillin and streptomycin. Cells were grown at 371C in 5% CO 2 .The cells were transfected during the log phase of their growth.
Using Superfectt Jurkat T cells at a concentration of 0.8 Â 10 6 cells/ml were transfected with 2.5 mg/ml plasmid DNA (85% Fas or FaslpGL3 enhancer vector construct and 15% Tyrosine Kinase-Promoter Renilla Luciferase internal vector control (Promega) TK-pRL vector) for 2 h.
The cells were then centrifuged and resuspended in RPMI and then left unstimulated or stimulated for 17 h with either PMA (25 pg/ml) or IFNg (200 ng/ml). These concentrations were found after titrations. In each experiment the individual constructs variants were included in triplicates. Cells were lysed and quantitation of luminescence was performed using the Dual-Luciferaset kit and a Lumat LB 9507 luminometer.
The activity of the individual constructs is expressed as mean ðof the triplicateÞ FaspGL3 Firefly activity= TK À pRL Renilla activity mean constitutive pGL3 Enhancer vector Firefly activity= TK À pl Renilla activity Firefly activity is normalized by the Renilla activity, and the results are expressed as the Firefly/Renilla ratio of activities.
Statistical analysis
Initially, the ANOVA (one-sided analysis of variance) was used to compare differences between groups and when significant at Po0.05, the t-test (paired) was used to compare experimental ratios between different clones. Results with a Po0.05 were considered significant. Results are shown as averages7standard error of the mean (s.e.m.).
